BUZZ-Organon rises as review finds no issues in past biosimilar purchases** Shares of healthcare firm Organon OGN.N rise 3.5% to $7.78 premarket
** Co says an independent review found no wrongdoing in how it recorded earlier purchases of biosimilars, which are lower‑cost versions of complex biologic drugs
** Co says its board audit committee launched the review after concerns were raised about timing of past biosimilar purchases; review found no need to revise past SEC filings
** Co says the annual report for 2025 will be filed on time
** Shares down ~52% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments